Currently, out of the existing stock ratings of Geoffrey Porges - 202 which are a Buy (64.95%), 107 which are a Hold (34.41%), 2 which are a Sell (0.64%)

Geoffrey Porges

Work Performance Price Targets & Ratings Chart

Analyst Geoffrey Porges works at LEERINK and is covering the Healthcare sector with 523 price targets and ratings displayed on 25 stocks.

Geoffrey Porges's average stock forecast success ratio is 68.87% with an average time for price targets to be met of 340.71 days.

Most recent stock forecast was given on RCUS, Arcus Biosciences at 04-Aug-2022.

Wall Street Analyst Geoffrey Porges

Analyst best performing recommendations are on TBPH (THERAVANCE BIOPHARMA).
The best stock recommendation documented was for TBPH (THERAVANCE BIOPHARMA) at 11/9/2016. The price target of $33 was fulfilled within 2 days with a profit of $2.63 (8.66%) receiving and performance score of 43.3.

Average potential price target upside

of $115.9 (26.33%) on REGN (REGENERON PHARMACEUTICALS).
of $67.63 (75.69%) on AXLA (AXCELLA HEALTH).
of $61.43 (23.04%) on BIIB (BIOGEN).

ABBV AbbVie ALXN AMGN Amgen ASMB Assembly Biosciences AXLA Axcella Health BIIB Biogen CELG FGEN FibroGen GILD Gilead Sciences MOR PAND PRNB RCUS Arcus Biosciences RDUS Radius Health REGN Regeneron Pharmaceuticals TBPH Theravance Biopharma XLRN Acceleron Pharma EPZM Epizyme HALO Halozyme Therapeutics VRTX Vertex Pharmaceuticals PFE Pfizer SNY ZGNX Zogenix AZN AstraZeneca PLC DOVA

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Carter Gould (BARCLAYS)